Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
56°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Marinus Pharmaceuticals
< Previous
1
2
3
Next >
Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA)
September 22, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 09, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million
August 29, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 12, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 11, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces U.S. Commercial Launch of ZTALMY® (ganaxolone) for Seizures Associated With CDKL5 Deficiency Disorder
July 28, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 15, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million
July 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 11, 2022
July 13, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus
June 08, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 03, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 12, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 10, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
May 05, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
April 20, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
April 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
April 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
March 31, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 21, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
March 18, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
February 22, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
February 16, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
February 10, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
February 03, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 14, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference
January 05, 2022
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
December 27, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting
December 03, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
November 22, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
November 15, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Tickers
MRNS
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.